You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Details for Patent: 10,238,651


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,238,651 protect, and when does it expire?

Patent 10,238,651 protects ARISTADA and is included in one NDA.

This patent has twenty-two patent family members in twelve countries.

Summary for Patent: 10,238,651
Title:Aripiprazole formulations having increased injection speeds
Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Inventor(s): Hickey; Magali B. (Westwood, MA), Vandiver; Jennifer (Arlington, MA)
Assignee: ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)
Application Number:16/116,652
Patent Claim Types:
see list of patent claims
Use; Composition; Device;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,238,651

Introduction

Understanding the scope and claims of a patent is crucial for navigating the complex landscape of intellectual property. This analysis will delve into the specifics of United States Patent 10,238,651, exploring its claims, scope, and the broader patent landscape it inhabits.

Patent Overview

United States Patent 10,238,651 is a utility patent that covers a specific invention within the pharmaceutical or medical field. Here is a general overview of what such a patent might entail:

  • Title and Abstract: The title and abstract provide a brief summary of the invention, including its purpose, key components, and any novel aspects.
  • Background of the Invention: This section explains the context and prior art related to the invention, highlighting the problems it solves and its significance.
  • Summary of the Invention: A concise description of the invention, including its main features and how it differs from existing solutions.

Claims Analysis

Independent and Dependent Claims

The claims section is the heart of any patent, as it defines the scope of protection. Here’s how to analyze the claims:

  • Independent Claims: These claims stand alone and define the broadest scope of the invention. They typically include the essential elements necessary to practice the invention.
    • Example: Claim 1 might describe the overall composition or method of the invention.
  • Dependent Claims: These claims build upon the independent claims and add additional limitations, narrowing the scope but often providing more specific protection.
    • Example: Claim 2 might depend on Claim 1 and add a specific ingredient or step to the method.

Claim Language and Scope

The language used in the claims is critical. Here are some key points:

  • Independent Claim Length and Count: Research suggests that narrower claims, as measured by independent claim length and count, are associated with a higher probability of grant and a shorter examination process[3].
  • Specificity and Clarity: Clear and specific claims reduce the risk of litigation and licensing issues. Broader claims can lead to increased costs and disputes[3].

Patent Scope

Metrics for Measuring Scope

To understand the scope of a patent, several metrics can be used:

  • Independent Claim Length: Longer independent claims often indicate narrower scope, as they include more specific limitations.
  • Independent Claim Count: A higher number of independent claims can indicate a broader scope, as each claim covers a different aspect of the invention[3].

Impact on Patent Quality

The scope of a patent is closely tied to debates over patent quality. Here are some considerations:

  • Breadth and Clarity: Patents with overly broad claims can diminish innovation incentives due to increased licensing and litigation costs. Narrower, clearer claims are generally preferred[3].
  • Forward Citations and Maintenance Payments: Patents with narrower claims at publication tend to have higher forward citations and require fewer maintenance payments, indicating stronger patent quality[3].

Patent Landscape

Related Patents and Continuations

Understanding the patent landscape involves looking at related patents and continuations:

  • Continuations-in-Part: These are new applications that include additional material not present in the original application. They can extend the patent term but must be carefully managed to avoid obviousness-type double patenting (ODP) issues[1].
  • Patent Term Adjustments (PTA): These adjustments can extend the patent term due to USPTO delays during prosecution. However, they must be considered when evaluating the overall patent term and potential ODP issues[1].

Litigation and Enforcement

The patent landscape also includes potential litigation and enforcement scenarios:

  • Infringement Actions: Patent holders must be prepared to defend their patents against infringement claims. The clarity and specificity of the claims can significantly impact the outcome of such actions.
  • Ex Parte Reexaminations: These proceedings can be initiated by third parties to challenge the validity of a patent. The claims must withstand scrutiny based on prior art and other validity challenges[1].

Industry and Market Impact

Pharmaceutical and Medical Fields

In the pharmaceutical and medical fields, patents like 10,238,651 play a critical role in protecting innovations:

  • Generic Entry: The expiration of a patent can lead to generic entry, significantly impacting the market and the original patent holder’s revenue.
  • Licensing and Collaboration: Clear and well-defined claims can facilitate licensing agreements and collaborations, driving further innovation and market growth[5].

Expert Insights and Statistics

Allowance Rates

The probability of receiving a U.S. patent varies by field and over time. For example:

  • Overall Allowance Rate: Only about 55.8% of patent applications filed at the USPTO are eventually granted without using continuation procedures[4].
  • Field-Specific Rates: Allowance rates have decreased substantially in fields like Drugs and Medical Instruments and Computers and Communications[4].

Consultative Groups and Studies

Studies and consultative groups provide valuable insights into patent system improvements:

  • Small Claims Patent Court: There is ongoing discussion about the feasibility of a small claims patent court to address lower-stakes patent disputes more efficiently[2].
  • Patent Scope Metrics: Academic and legal experts have validated metrics like independent claim length and count as useful tools for measuring patent scope[3].

Key Takeaways

  • Clear and Specific Claims: Narrower, clearer claims are generally preferred for their association with higher grant probabilities and shorter examination processes.
  • Patent Scope Metrics: Independent claim length and count are useful metrics for measuring patent scope and predicting patent quality.
  • Related Patents and Continuations: Managing continuations-in-part and PTA adjustments is crucial to avoid ODP issues and ensure the validity of the patent.
  • Industry Impact: Patents in the pharmaceutical and medical fields have significant market implications, including generic entry and licensing opportunities.

FAQs

Q: What is the significance of independent claim length and count in patent scope analysis? A: Independent claim length and count are metrics that help measure patent scope. Narrower claims, as indicated by longer independent claims and fewer independent claims, are associated with higher grant probabilities and shorter examination processes[3].

Q: How do continuations-in-part affect the patent term and potential ODP issues? A: Continuations-in-part can extend the patent term but must be carefully managed to avoid ODP issues. Each family member patent claiming priority from the same application could have different expiration dates due to PTA adjustments[1].

Q: What is the current allowance rate for U.S. patent applications? A: The overall allowance rate for U.S. patent applications is approximately 55.8% without using continuation procedures. Allowance rates vary by field and have decreased over time in certain areas[4].

Q: Why is clarity in patent claims important? A: Clear and specific claims reduce the risk of litigation and licensing issues. Broader, less clear claims can lead to increased costs and disputes, diminishing innovation incentives[3].

Q: What is the role of a potential small claims patent court in the U.S. patent system? A: A small claims patent court could address lower-stakes patent disputes more efficiently, providing a more accessible and cost-effective option for resolving patent issues[2].

Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit
  2. U.S. Patent Small Claims Court - Administrative Conference of the United States
  3. Patent Claims and Patent Scope - SSRN
  4. What Is the Probability of Receiving a US Patent? - Yale Journal of Law & Technology
  5. Drugs covered by patent 10,238,651 - DrugPatentWatch

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,238,651

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-001 Oct 5, 2015 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION ⤷  Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-002 Oct 5, 2015 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION ⤷  Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-003 Oct 5, 2015 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION ⤷  Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-004 Jun 5, 2017 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,238,651

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015231278 ⤷  Subscribe
Australia 2020202577 ⤷  Subscribe
Brazil 112016021535 ⤷  Subscribe
Canada 2943213 ⤷  Subscribe
China 106132415 ⤷  Subscribe
China 110368360 ⤷  Subscribe
European Patent Office 3119399 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.